Perspective Therapeutics (CATX) Income towards Parent Company (2010 - 2026)
Perspective Therapeutics (CATX) posted Income towards Parent Company of -$28.9 million for Q1 2026, down 5727.43% sequentially from $514000.0 in Q2 2025.
Perspective Therapeutics (CATX) Income towards Parent Company (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Income towards Parent Company for 17 years, with the latest figure at -$28.9 million in Q1 2026.
- Quarterly Income towards Parent Company changed N/A year-over-year to -$28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.4 million (down 5698.16% YoY) and the FY2025 annual result came in at $514000.0, up 154.16% from the prior year.
- Income towards Parent Company eased to -$28.9 million in Q1 2026 per CATX's latest filing, from $514000.0 in the prior quarter.
- Over five years, Income towards Parent Company peaked at $514000.0 in Q2 2025 and troughed at -$28.9 million in Q1 2026.
- A 5-year average of -$4.4 million and a median of -$1.5 million in 2023 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company slumped 1046.13% in 2022, then jumped 204.9% in 2025.
- Over 5 years, Income towards Parent Company stood at -$2.3 million in 2022, then slumped by 127.82% to -$5.2 million in 2023, then soared by 90.55% to -$490000.0 in 2024, then surged by 204.9% to $514000.0 in 2025, then slumped by 5727.43% to -$28.9 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$28.9 million, $514000.0, and -$490000.0 for Q1 2026, Q2 2025, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn |
| 10 | Perspective Therapeutics | 384.27 Mn | 384.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 197,000.00 |
| Mar 31, 2026 | -28.93 Mn |
| Jun 30, 2025 | 514,000.00 |
| Jun 30, 2024 | -490,000.00 |
| Mar 31, 2024 | -459,000.00 |
| Dec 31, 2023 | -5.18 Mn |
| Sep 30, 2023 | -784,000.00 |
| Jun 30, 2023 | -1.62 Mn |
| Mar 31, 2023 | -1.47 Mn |
| Dec 31, 2022 | -2.28 Mn |
| Sep 30, 2022 | -7.49 Mn |
| Jun 30, 2022 | -3.43 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Dec 31, 2021 | -1.60 Mn |
| Sep 30, 2021 | -2.59 Mn |
| Jun 30, 2021 | 362,000.00 |
| Mar 31, 2021 | -3.13 Mn |
| Dec 31, 2020 | -1.13 Mn |
| Sep 30, 2020 | -987,000.00 |
| Jun 30, 2020 | -1.42 Mn |